Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab

BACKGROUND: The development of pulmonary immune-related adverse events (irAEs) in patients undergoing PD-(L)1 targeted checkpoint inhibitors are rare, but may be life-threatening. While many published articles and guidelines are focusing on the presentation and upfront treatment of pulmonary irAEs,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortega Sanchez, Guacimara, Jahn, Kathleen, Savic, Spasenija, Zippelius, Alfred, Läubli, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122461/
https://www.ncbi.nlm.nih.gov/pubmed/30176946
http://dx.doi.org/10.1186/s40425-018-0400-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122461/
https://www.ncbi.nlm.nih.gov/pubmed/30176946
http://dx.doi.org/10.1186/s40425-018-0400-4

Ejemplares similares